Gilead signs deals with Indian companies for low-cost HIV drug
(Reuters) - Gilead Sciences Inc signed deals with three Indian companies to drive sales and reduce manufacturing costs of low-cost generic versions of its HIV drug emtricitabine in developing countries.
Under deals with Ranbaxy Laboratories, Strides Arcolab and Mylan Inc's India unit, Gilead will provide technology and funding to help reduce manufacturing costs of the drug, the companies said.
Gilead, which sells the drug under the Emtriva brand, is the world's largest maker of branded drugs to treat the human immunodeficiency virus -- the cause of AIDS.
(Reporting by Shailesh Kuber; Editing by Viraj Nair)
- Tweet this
- Share this
- Digg this
- OPEC oil output hits highest since 2012 on Libya, Saudi-Reuters Survey
- With iPhone 6 approved in China, Apple suppliers ready for demand
- Energy, manufacturing to lead Modi, Obama talks
- Modi promises U.S. CEOs a return to market reforms
- Kurds seize Iraq/Syria border post; Sunni tribe joins fight against Islamic State
Children represent just 15 percent of the recorded 3,091 Ebola deaths recorded mostly in Liberia, Sierra Leone and Guinea. But that number masks the broader impact the disease is having on children. Fear of contagion means many orphans, even those who test negative, are being abandoned. Full Article